RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+64.05%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.61B
AUM Growth
+$2.61B
(+13%)
Cap. Flow
+$43.5M
Cap. Flow
% of AUM
1.67%
Top 10 Holdings %
Top 10 Hldgs %
53.33%
Holding
82
New
6
Increased
24
Reduced
27
Closed
10
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$183M |
| 2 |
Krystal Biotech
KRYS
|
$76.7M |
| 3 |
Cogent Biosciences
COGT
|
$24.3M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$23.9M |
| 5 |
Zimmer Biomet
ZBH
|
$22M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$102M |
| 2 |
argenx
ARGX
|
$48.6M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
$41.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$31.9M |
| 5 |
Bristol-Myers Squibb
BMY
|
$31.2M |
Sector Composition
| 1 | Healthcare | 97.02% |
| 2 | Industrials | 2.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ventyx Biosciences
VTYX
$184M
| $30.8M | 1.18% |
940,493
+124,719
| +15% | +$4.09M |
|
27
ADC Therapeutics
ADCT
$370M
| $30.2M | 1.16% |
14,049,935
+484,686
| +4% | +$1.04M |
|
28
Nurix Therapeutics
NRIX
$723M
| $28.5M | 1.1% |
2,857,309
+107,925
| +4% | +$1.08M |
|
|
IGMS
29
DELISTED
IGM Biosciences
IGMS
| $27.4M | 1.05% |
2,971,542
-362,813
| -11% | -$3.35M |
|
30
Stryker
SYK
$149B
| $26.2M | 1.01% |
85,899
-50,565
| -37% | -$15.4M |
|
31
Repare Therapeutics
RPTX
$73.9M
| $25.7M | 0.99% |
2,428,335
-104,715
| -4% | -$1.11M |
|
|
32
Cogent Biosciences
COGT
$1.83B
| $24.3M | 0.93% |
+2,053,333
| New | +$24.3M |
|
33
Charles River Laboratories
CRL
$7.99B
| $24M | 0.92% |
114,351
-977
| -0.8% | -$205K |
|
|
34
Zimmer Biomet
ZBH
$20.8B
| $22M | 0.85% |
+151,372
| New | +$22M |
|
35
IQVIA
IQV
$31.4B
| $21.2M | 0.81% |
94,409
+22,752
| +32% | +$5.11M |
|
36
Boston Scientific
BSX
$159B
| $21.2M | 0.81% |
391,178
+219,398
| +128% | +$11.9M |
|
37
Humana
HUM
$37.5B
| $20.7M | 0.79% |
46,310
-5,769
| -11% | -$2.58M |
|
|
VERV
38
DELISTED
Verve Therapeutics
VERV
| $19.9M | 0.76% |
1,061,960
-58,719
| -5% | -$1.1M |
|
39
Entrada Therapeutics
TRDA
$202M
| $19.9M | 0.76% |
1,311,572
-520,036
| -28% | -$7.87M |
|
40
Prime Medicine
PRME
$595M
| $19.4M | 0.74% |
1,324,350
-668,493
| -34% | -$9.79M |
|
41
Cabaletta Bio
CABA
$144M
| $17.7M | 0.68% |
1,370,299
+1,096,047
| +400% | +$14.1M |
|
42
Shattuck Labs
STTK
$61.3M
| $17.5M | 0.67% |
5,619,914
| – | – |
|
43
89bio
ETNB
$1.37B
| $14.4M | 0.55% |
761,955
-138,045
| -15% | -$2.62M |
|
|
GRTS
44
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $13.4M | 0.51% |
6,860,226
-66,700
| -1% | -$130K |
|
45
Annexon
ANNX
$225M
| $12.3M | 0.47% |
3,503,190
| – | – |
|
46
Absci
ABSI
$356M
| $12.2M | 0.47% |
8,031,094
| – | – |
|
|
ALLK
47
DELISTED
Allakos
ALLK
| $9.96M | 0.38% |
2,283,594
-2,583
| -0.1% | -$11.3K |
|
48
Stereotaxis
STXS
$246M
| $9.75M | 0.37% |
6,373,898
+4,886,403
| +328% | +$7.48M |
|
49
Atara Biotherapeutics
ATRA
$88.7M
| $9.74M | 0.37% |
6,048,123
+436,067
| +8% | +$702K |
|
50
ALX Oncology
ALXO
$54.6M
| $9.64M | 0.37% |
1,283,289
+696,312
| +119% | +$5.23M |
|